Wide Ranks

CGEM

Cullinan Therapeutics, Inc.

13.09

Top Statistics
Market Cap 762 M Forward PE -4.18 Revenue Growth 0.00 %
Current Ratio 24.46 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.9970 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 578 M Total Cash Per Share 9.93 Total Debt 2 M
Total Debt To Equity 0.3900 Current Ratio 24.46 Book Value Per Share 10.80
All Measures
Short Ratio 1800.00 % Message Board Id finmb_539392639 Shares Short Prior Month 9 M
Return On Equity -0.2653 City Cambridge Uuid df7e2588-017b-3d57-acc4-780da62c5adc
Previous Close 12.77 First Trade Date Epoch Utc 1 B Book Value 10.80
Beta -0.1170 Total Debt 2 M Volume 457925
Price To Book 1.21 Fifty Two Week Low 7.64 Total Cash Per Share 9.93
Shares Short Previous Month Date 1 B Target Median Price 33.00 Max Age 86400
Recommendation Mean 1.20 Sand P52 Week Change 0.3133 Target Mean Price 33.00
Net Income To Common -143539008 Short Percent Of Float 0.1734 Implied Shares Outstanding 58 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 581070
Average Volume10days 581070 Total Cash 578 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0449 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 12.77 Target Low Price 28.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 15.77 Open 12.82
Free Cashflow -81790496 State MA Dividend Yield 0.00 %
Return On Assets -0.2040 Time Zone Short Name EST Trailing Eps -2.84
Day Low 12.43 Address1 One Main Street Shares Outstanding 58 M
Price Hint 2 Target High Price 40.00 Website https://cullinantherapeutics.com
52 Week Change 0.5983 Average Volume 538065 Forward Eps -3.25
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 2388.40 %
Is_sp_500 False Regular Market Day High 13.11 Profit Margins 0.00 %
Debt To Equity 0.3900 Fifty Two Week High 30.19 Day High 13.11
Shares Short 8 M Regular Market Open 12.82 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.1496
Operating Cashflow -126808000 Currency USD Time Zone Full Name America/New_York
Market Cap 762 M Is_nasdaq_100 False Zip 02142
Quote Type EQUITY Industry Biotechnology Long Name Cullinan Therapeutics, Inc.
Regular Market Day Low 12.43 Held Percent Institutions 1.18 Current Price 13.09
Address2 Suite 1350 Enterprise To Ebitda -0.9970 Financial Currency USD
Current Ratio 24.46 Industry Disp Biotechnology Number Of Analyst Opinions 9
Country United States Float Shares 38 M Two Hundred Day Average 18.30
Enterprise Value 186 M Forward PE -4.18 Regular Market Volume 457925
Ebitda -187050000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States.

The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors.

Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma.

It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co.

, Ltd to develop Zipalertinib.

Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024.

Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.